Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on March 12 that it has successfully produced a viable vaccine candidate for COVID-19 just 20 days after obtaining the gene of the novel coronavirus causing the disease. Medicago said that…
To read the full story
Related Article
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Govt Officials Urge Japan Pharma Companies to Be More Proactive in Coronavirus Vaccine Development
May 12, 2020
BUSINESS
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
March 18, 2026
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





